Compare Amgen, Inc. (AMGN) vs Campbell Soup Co. (CPB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Campbell Soup Co. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Campbell Soup Co. trades at $22.15 (market cap $6.58B). The key difference: Amgen, Inc. is far larger — about 29.8× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (7.07%). Which is the better fit depends on your goals.
| AMGN | CPB | |
|---|---|---|
Market Cap | $196.12B | $6.58B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $34.03 |
52-Week Low | $271.18 | $20.00 |
Enterprise Value | $241.41B | $13.19B |
Dividend Yield | 2.77% | 7.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Campbell's (CPB) trades at $22.07, up 2.79% today, with a bearish technical signal and mixed earnings history. The stock shows attractive valuation metrics with a P/E of 10.82 and P/S of 0.67, but profitability remains modest with a 6.12% net margin. Recent news highlights cost-cutting efforts and a 7% dividend yield, though sales declines and margin pressures persist.
Outlook is cautious due to weak analyst consensus (only 3.45% buy ratings) and structural margin challenges. The stock offers value and income potential but faces headwinds from inflation and competitive pressures. Risks include execution on cost savings and consumer demand volatility, with the consensus price target at $20.00 suggesting limited upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →
